恩替卡韦联合胸腺素α1治疗慢性乙型肝炎患者疗效及其外周血T淋巴细胞亚群的变化

doi:10.3969/j.issn.1672-5069.2018.03.035

Abstract

Li Tianjun, Ma Hui. Entecavir combined with thymosin-alpha 1 in treatment of patients with chronic hepatitis B[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(3): 455-456.

[1] Liaw YF.Thymalfasin (thymosin-alpha 1) therapy in patients with chronic hepatitis B. J Gastroenterol Hepatol,2004,19(12):S73-75.
[2] 江宇泳,叶永安,刘遥. 慢性乙型肝炎合并脂肪肝的临床特征.中国临床医生杂志,2015,43(6):32-35.
[3] Lee HW,Lee JI,Um SH,et al.Combination therapy of thymosin alpha-1 and lamivudine for HBeAg positive chronic hepatitis B:A prospective randomized,comparative pilot study.J Gastroenterol Hepatol,2008,23(5):729-735.
[4] Wu X,Jia J,You H.Thymosin alpha-1 treatment in chronic hepatitis B. Expert Opin Biol Ther,2015,12(1):S129-132.
[5] Lau GK,Nanji A,Hou J,et al.Thymosin-alpha1 and famciclovir combination therapy activates T-cell response in patients with chronic hepatitis B virus infection in immune-tolerant phase.J Viral Hepat,2002,9(4):280-287.
[6] Saruc M,Ozden N,Turkel N,et al.Long-term outcomes of thymosin-alpha 1 and interferon alpha-2b combination therapy in patients with hepatitis B e antigen(HBeAg) negative chronic hepatitis B. J Pharm Sci,2003,92(7):1386-1395.
[7] Yang YF,Zhao W,Zhong YD,et al.Comparison of the efficacy of thymosin alpha-1 and interferon alpha in the treatment of chronic hepatitis B:a meta-analysis. Antiviral Res,2008,77(2):136-141.
[8] Almeida SMD,Bhatt A,Riggs PK,et al.Cerebrospinal fluid human immunodeficiency virus viral load in patients with neurosyphilis. J Neurovirol,2010,16(1):6-12.
[9] 谢晶日,李婷婷,李明,等. 慢性乙型病毒性肝炎免疫耐受的研究进展. 中华中医药学刊,2014,32(1):13-14.
[10] Iino S,Toyota J,Kumada H,et al.The efficacy and safety of thymosin alpha-1 in Japanese patients with chronic hepatitis B; results from a randomized clinical trial. J Viral Hepat,2005,12(3):300-306.
[11] Qiu SJ,Zhou ZG,Shen F,et al.A multicenter,randomized,observation-controlled clinical trial to evaluate the efficacy and safety of thymalfasin adjuvant therapy in patients with HBV-related HCC after curative resection-first announcement of the protocol.Expert Opin Biol Ther,2015,15(1):S133-137.
[12] Lau GK,Piratvisuth T,Luo KX,et al.Peginterferon alfa-2a,lamivudine,and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med,2005,352(26):2682-2695.
[13] 柴艳云,李建国,张新龙,等. 阿德福韦酯与恩替卡韦治疗HBeAg阳性慢性乙型肝炎患者临床疗效观察.实用肝脏病杂志,2014,17(3):307-308.

[1]	Bao Yingjun, Ren Weixin.. Interventional therapy for patients with portal vein thrombosis [J]. Journal of Practical Hepatology, 2019, 22(6): 768-769.
[2]	National Workshop on Fatty Liver, Alcoholic Liver Disease, Chinese Society of Hepatology; National Workshop on Liver, Metabolism, Chinese Society of Endocrinology, Chinese Medical Association. Committee of Hepatology, Chinese Research Hospital Association; Fatty Liver Expert Committee, Chinese Medical Doctor Association [J]. Journal of Practical Hepatology, 2019, 22(6): 787-792.
[3]	chronic hepatitis B Zhu Lingyun, Zhang Maohai Cui Shasha, et al.. Serum IL-12 and IL-18 levels as well as peripheral blood mononuclear cell FOXp3 in patients with [J]. Journal of Practical Hepatology, 2019, 22(6): 816-819.
[4]	Shi Yingying, Wang Yuanxi.. Impact of combination telbivudine and adefovir dipivoxil on renal functions in the treatment of patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(6): 820-823.
[5]	Min Feng, Huang Wenqi, Wu Weibing, et al.. Implications of serum adipocytokine levels in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(6): 824-827.
[6]	patients with chronic hepatitis B Zhang Yingming, Shen Shuang, Tian Fei, et al.. Prediction of response to peginterferon alfa-2a by blood IFNL4 and IL-28B gene polymorphisms in [J]. Journal of Practical Hepatology, 2019, 22(6): 828-831.
[7]	chronic hepatitis B virus carriers Wu Haiyi, Chen Jianxin.. Diagnostic efficacy of four non-invasive diagnostic models in evaluating significant liver fibrosis in [J]. Journal of Practical Hepatology, 2019, 22(6): 832-835.
[8]	Ma Liying, Shen Lijuan.. Efficacy and safety of tenofovir in the treatment of pregnant women with high HBV DNA loads [J]. Journal of Practical Hepatology, 2019, 22(6): 836-839.
[9]	Xing Xin, Wei Zhongcao, Zhou mimi, et al.. Efficacy and safety of tauroursodeoxycholic acid and ursodeoxycholic acid combination in the treatment of patients with nonalcoholic fatty liver disease:a Meta-analysis [J]. Journal of Practical Hepatology, 2019, 22(6): 852-855.
[10]	Duan Chuyao, Chen Qingshan, Wang Liming, et al.. Clinical efficacy of ursodeoxycholic acid in treatment of patients with intrahepatic cholestasis of pregnancy [J]. Journal of Practical Hepatology, 2019, 22(6): 864-867.
[11]	Chen Meimei, Duan Xiaoyan, Cao Haixia, et al.. Improvement of clinical symptoms and serum hepatic fibrosis markers in patients with primary biliary cirrhosis by compound Biejiaruangan tablets [J]. Journal of Practical Hepatology, 2019, 22(6): 880-883.
[12]	Ma Yaqiong, Li Zhilan, Xia Bing.. Early administration of enteral nutrition and microecological agents in patients with hepatic encephalopathy [J]. Journal of Practical Hepatology, 2019, 22(6): 892-895.
[13]	Feng Wenguang, Jiang Wei, Song Guojun.. PPV-guided fluid therapy in patients with hepatolithiasis underwent partial hepatectomy [J]. Journal of Practical Hepatology, 2019, 22(6): 912-915.
[14]	Li Qiuxi, Jia Jianfeng, Huang Rui.. Clinical value of segmental pedicle hepatectomy and B-ultrasound-guided hepatectomy in the treatment of patients with hepatolithiasis [J]. Journal of Practical Hepatology, 2019, 22(6): 916-919.
[15]	Li Chuanjie, Xu Jing, Wang Liangliang, et al.. Changes of serum HBsAg levels in patients with chronic hepatitis B receiving entecavir treatment [J]. Journal of Practical Hepatology, 2019, 22(6): 928-929.

Entecavir combined with thymosin-alpha 1 in treatment of patients with chronic hepatitis B

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments